Company Focus
Icon
Latest Icon News
Biotechnology
Irish contract research organization ICON has retained its position as the most active CRO worldwide in the first quarter of 2025, according to a new analysis by GlobalData. 16 May 2025
Related News
Insights
Company Spotlight
A global biotech developing of novel antibody-based drugs with innovative technologies.
Latest News & Features of interest to Icon
Biotechnology
A quiet shift with potentially big implications for cancer drug access is underway in the UK. In June, the country’s health technology assessor, NICE, recommended GSK’s Blenrep (belantamab mafodotin) in multiple myeloma. 14 July 2025
Pharmaceutical
Germany’s Bayer has announced that the US Food and Drug Administration (FDA) has approved Kerendia (finerenone) to treat patients with heart failure (HF) with left ventricular ejection fraction (LVEF) ≥40%, following the agency’s Priority Review of its supplemental New Drug Application (sNDA). 14 July 2025
Pharmaceutical
Italian pharma major Recordati presented four poster presentations and one product theater featuring the company’s endocrinology portfolio at the Endocrine Society’s annual meeting, ENDO 2025, taking place in San Francisco, California,
including a presentation relating to the expanded indication of Isturisa (osilodrostat) for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome. 14 July 2025
Biotechnology
The Amsterdam District Court has delivered a ruling in the lawsuit brought by Farma ter Verantwoording (FtV) — The Pharmaceutical Accountability Foundation— against US drugmaker AbbVie. 14 July 2025
Pharmaceutical
UK pharma major AstraZeneca today announced positive high-level results from the baxdrostat BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension. 14 July 2025
Pharmaceutical
China’s vaccine landscape is shifting after local biotech Xiamen Innovax Biotech unveiled the country’s first domestically developed nine-valent HPV vaccine, Cecolin 9, at a price far below that of the incumbent Gardasil 9. The new shot is being offered at around $70 per dose—less than half the typical price of Merck & Co’s (NYSE: MRK) product in the country. 14 July 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of Bayer's Lynkuet (elinzanetant) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. 14 July 2025
Pharmaceutical
US biotech Crinetics Pharmaceuticals has released new data on its investigational oral therapy Palsonify (paltusotine), supporting its potential as a convenient alternative to monthly injections for patients with acromegaly. 14 July 2025
Biotechnology
Ultragenyx Pharmaceutical has been dealt a regulatory setback, as the American medicines regulator has declined to approve its gene therapy UX111 (formerly ABO-102) for Sanfilippo syndrome type A. The decision, delivered in a complete response letter, will delay any potential approval until at least 2026. 14 July 2025
Biotechnology
US late-stage oncology-focused Revolution Medicines and Iambic Therapeutics, which is developing novel medicines using its AI-driven discovery and development platform, today announced a technology and research collaboration to pursue novel drug candidates using Iambic’s leading AI models. 13 July 2025
Latest In Brief for Icon
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest Relevant Ones To Watch News
US pharma giant Merck & Co today revealed it has made a bid to acquire UK-based lung therapy company Verona Pharma, sending the latter’s shares up 20.4% to $104.61 in pre-market activity. 13 July 2025
30 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze